People · Operator
Named in public records as an officer, director or promoter · active 2012–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Exosome Diagnostics, Inc. | — | Biotechnology | Series B | $90.9M | $1.2B | 2012 |
Joseph Slattery at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joseph Slattery on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William Kelly | 1 | 5 |
| Georg Nebgen | 1 | 5 |
| David Okrongly | 1 | 4 |
| John Boyce | 1 | 4 |
| James McCullough | 1 | 3 |
| Sara Barrington | 1 | 3 |
| Joseph Boystak | 1 | 2 |
| Kapil Dhingra | 1 | 2 |
| Thomas McLain | 1 | 2 |
| Geert-Jan Mulder | 1 | 2 |
| Peter Johann | 1 | 2 |
| Steven Soignet | 1 | 1 |
| Greg Zdechlik | 1 | 1 |
| Wayne Comper | 1 | 1 |
| Dhingra Kapil | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.